CCR5-delta32 status appears to have several beneficial effects on the alloHSCT setting: previous analyses revealed that the CCR5-delta32 allele appears to protect against acute graft versus host disease (GVHD) and EBV reactivation [8,9]. The gene discussed is CCR5; the disease is graft versus host disease.